15 / 17
What happens in 2018?
Erlotinib+Beva
Dacomitinib
Osimertinib
8-13 m
16 m
19 m
Corral J, et al. ELCC 2017; Oxnard G, et al. IASLC 2017
Wu YL, et al. Lancet Oncol 2017; Capuzzo F. Appl Clin Genet 2017
Gefitinib
Erlotinib
Afatinib
Resistance?
OS?
ASCO 2018